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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Cardiovascular complication is the leading cause of mortality in patients
with diabetes. Dyslipidemia and hypertension are the major risk factors contributing to cardio-
vascular disease (CVD). This study was carried out to investigate the prevalence of dyslipide-
mia and hypertension and their associations with microvascular and macrovascular
complications in patients with type 2 diabetes in Taiwan.
Methods: Health-care data and diagnostic codes were retrieved from the Taiwan Bureau of
National Health Insurance claims files for the years 2000e2009. Based on these data the annual
prevalences of dyslipidemia and hypertension were calculated and patients were stratified by
age, gender, and diabetic complications.of Internal Medicine, Taichung Veterans General Hospital, Number 160, Section 3, Chung Kang Road,
hi Relief Institute, 200 Guangzhou Street, Taipei, Taiwan.
(T.-Y. Tai), whhsheu@vghtc.gov.tw (W.H.-H. Sheu).
to this study.
ight ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.
2.09.010
626 L.-N. Tseng et al.Results: In patients with diabetes, the prevalence of dyslipidemia increased with age, with the
highest rate recorded in adults (inclusive of both genders) between 40 and 65 years of age
(p for trend <0.001). The prevalence of hypertension also increased with age with the highest
rate seen in adults (inclusive of both genders) >65 years of age (p for trend <0.001). The prev-
alence of stroke and CVD decreased gradually (p for trend 0.025 and <0.001, respectively),
while the prevalence of peripheral vascular disease (PVD) increased in patients with diabetes
during the study period (p for trend <0.001). The prevalence of dyslipidemia increased in dia-
betic patients with eye diseases and in men with nephropathies, but decreased in women with
nephropathies during the study period. In contrast, the prevalence of dyslipidemia decreased
in patients with macrovascular complications, including CVD and cerebrovascular disease
(cerebrovascular accident), but increased in those patients with PVD (p for all trends
<0.05). In diabetic patients with various macrovascular complications, except PVD, there
was a decrease in the prevalence of hypertension in the past 10 years. The prevalence of
hypertension increased in patients with microvascular complications including retinopathy,
patients on dialysis (inclusive of both genders), and in men with nephropathy. The prevalence
of hypertension along with dyslipidemia increased in patients with microvascular complica-
tions including retinopathy, patients on dialysis (inclusive of both genders), and in men with
nephropathy; however, the rate decreased in all macrovascular complications except in PVD.
Conclusion: Although progressively increased prevalence of dyslipidemia and hypertension was
observed in patients with diabetes in Taiwan, there was a decrease in the prevalence of stroke
and CVD in the past 10 years. Among those with macrovascular diseases, except PVD, there was
a trend of decreased prevalence of hypertension and dyslipidemia during the study period. In
patients with microvascular diseases, prevalence of hypertension and dyslipidemia in patients
with eye diseases increased in the past 10 years. More aggressive management of different risk
factors is warranted in diabetic patients with various vascular diseases.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
The number of people with diabetes mellitus worldwide is
soaring with the largest number, an estimated 131.9
million, reported in the Western Pacific region.1 The
number of cases with diabetes in Taiwan is also increasing.
According to the claims database of the Taiwan National
Health Insurance (NHI) program, the age-standardized
prevalence of diabetes in Taiwan increased from 4.7% to
6.5% for men and from 5.3% to 6.6% for women between
1999 and 2004.2
Type 2 diabetes is associated with significant morbidity
and mortality due to cardiovascular complications.3 Dysli-
pidemia, an established risk factor for cardiovascular
disease (CVD), affects almost 50% of the patients with type
2 diabetes in the United States.4 In addition to hypergly-
cemia and hypertension, dyslipidemia is a modifiable CVD
risk factor that remains largely uncontrolled in patients
with type 2 diabetes.5
Hypertension is another major modifiable risk factor of
CVD. In Taiwan, more than 50% of the elderly people are
hypertensive.6 In the United States, approximately 75% of
patients with diabetes have concomitant hypertension.7
There is a significant amount of overlap between the
complications of diabetes and hypertension, namely,
systemic vascular diseases.
Although advances have been made in the treatment of
diabetic complications, cardiovascular complications are
still the leading cause of mortality in people with diabetes.
Macrovascular complications, including CVD, cerebrovas-
cular disease (cerebrovascular accident or CVA), andperipheral vascular disease (PVD), are the most common
causes of mortality in patients with diabetes.8 Because
different methodologies are used to access the complica-
tions, there are wide demographic and geographical
differences in the prevalence of macrovascular complica-
tions among cohorts of patients with diabetes.8
To better understand the prevalence of dyslipidemia and
hypertension along with macrovascular and microvascular
complications in patients with diabetes and their trends in
recent years, data from the claims database of the Taiwan
NHI program from 2000 to 2009 were retrieved and
analyzed.Methods
Patients and methods
Data source
A universal compulsory NHI program was initiated by the
Taiwanese government in March 1995.9 It provided
coverage for 95% of the total population of 22.3 million in
Taiwan in 2000, with the coverage increasing to 98% in 2005
and 99.6% in 2009. Large computerized administrative and
claims data sets derived from this program have been
maintained on an ongoing basis by the Collaboration Center
of Health Information Application, the Department of
Health (DOH), Executive Yuan, and are made available to
investigators for research purposes after personal health
information is scrambled. The DOH Mortality Registry also
scrambles personal data to link them with the NHI claims
Prevalence of hypertension and dyslipidemia in Taiwan diabetic patients 627data. In this study, inpatient and outpatient claims data
sets from 2000 to 2009 were used. This study was approved
by the Institutional Review Board of National Taiwan
University Hospital.
Selection of cases
The diagnostic code 250 used for diabetes mellitus was
based on the International Classification of Diseases, 9th
Revision with Clinical Modification (ICD-9-CM) coding
system. Before June 2000, an A code (A181) was used for
outpatients only. For privacy reasons, NHRI provided data
for only one-third of the randomly sampled patients who
were identified as having been hospitalized or having made
an ambulatory visit for diabetes (ICD-9-CM code 250 and A
code A181) from 2000 to 2009. Patients were classified as
having diabetes and included in the analysis if they had at
least one admission code of diabetes or three or more
outpatient codes of diabetes within 365 calendar days. To
avoid the inclusion of misdiagnosed patients, we used the
aforementioned selection criteria every year.10
The definition of dyslipidemia and hypertension
If the eligible patients with diabetes had also prescribed an
Anatomical Therapeutic Chemical code C10 (lipid modifying
agents) drug for disease treatment for either outpatient or
inpatient care in index year, they were considered to have
a diagnosis of dyslipidemia. If the eligible patients with
diabetes who also had at least two diagnosis of hyperten-
sion (ICD-9-CM: 401e405 and A code A26) for either
outpatient or inpatient care within 365 calendar days, then
they were considered to have a diagnosis of hypertension.
Demographic characteristics
Demographic information such as patient’s age and gender
were obtained directly from the Bureau of NHI files. The
patient’s age was divided into three categories: <40,
40e65, and >65 years. Diabetes-related complications
defined using ICD-9, op, or A codes are listed below:
(1) Eye diseases
(1a) All kinds of eye disease: 362.01, 362.02, 362.53, 362.83,
364.42, 379.23, 369.xx, 14.2x-14.5x, 14.7 (A232)
(1b) Blindness and low vision: 369.xx/photocoagulation
14.23, 14.24, 14.25, 14.33, 14.34, 14.35, 14.53, 14.54,
14.55/surgery: 14.21, 14.22, 14.26, 14.27, 14.29,
14.31, 14.32, 14.39, 14.4, 14.51, 14.52, 14.59, 14.7
(2) PVD
(2a) All kinds of PVD: 440.2x, 443.9, 84.1x, 39.25, 39.29,
39.50, 39.59 (A300, A301, A302)
(2b) Amputation of lower limb: 84.1x (nontraumatic,
excluding ICD 800-999)/blood vessel bypass surgery:
39.25, 39.29, 39.59/percutaneous transluminal angio-
plasty (PTA) 39.50
(3) CVD
(3a) All kinds of CVD: 398.91, 402, 404, 410, 411, 412, 413,
414, 428, 36.xx, (A260, A27, A270, A25, A250, A251)
(3b) Myocardial infarction (MI): 410 (acute MI), 412 (old
MI)/coronary artery bypass graft (CABG) 36.1x/percu-
taneous transluminal coronary angioplasty (PTCA)
36.01, 36.02, 36.05, 00.66/stent 36.06, 36.07
(4) Stroke(4a) All kinds of stroke: 430, 431, 432, 433, 434, 435, 436,
785.9 (A290eA294)
(5) Kidney disease
(5a) All kinds of nephropathy: 250.4, 403, 404, 585, 586,
581.8x, 791.0, 593.9, v42.0, v45.1, v56.0, v56.8, 39.27,
39.42, 39.43, 39.49, 39.50, 39.53, 39.93, 39.94, 39.95
(A350)
(5b) Chronic renal failure: 585/renal transplantation V42.0/
dialysis 39.95, v45.1, v56.0, v56.8, [CURE_ITEM_NO1-4]:
D8 (hemodialysis), D9 (peritoneal dialysis)
(6) Foot disease
(6a) All kinds of foot infection: foot gangrene 040.0,
440.24, 785.4 with 250.7 or 440.2, 440.21, 440.22, and
440.23/foot osteomyelitis: 730.07, 730.17, 730.27,
730.97, 440.23, 707.14, 707.15, 707.1/cellulitis or
abscess of the foot: 680.7, 682.7, 681.1, 681.10
(6b) Foot amputation (ICD-9-CM codes): V49.71e77; V52.1
and (ICD-9 procedure codes): 84.11e17Statistical analysis
We performed a trend analysis to investigate the trends of
prevalence of hypertension and/or dyslipidemia among
patients with type 2 diabetes stratified by gender and age
from 2000 to 2009. We also used Kendall tau-c coefficient to
measure the strength of associations across the years 2000,
2004, and 2008 in diabetic patients with hypertension/
dyslipidemia, and those with macrovascular and microvas-
cular complications stratified by gender and age.
Results
Analysis of claims data from the Taiwan NHI database
showed that the prevalence of both hypertension and dys-
lipidemia in patients with type 2 diabetes increased year by
year from 2000 to 2008 (p for trend <0.001). The preva-
lence of diabetes with hypertension plus dyslipidemia
increased by more than twofold, from 13.52% to 31.01% in
women and from 10.47% to 25.65% in men from 2000 to 2008
(Table 1). In both genders, the peak age for dyslipidemia
was 40e65 years, while the peak age for hypertension was
>65 years (p for all trends <0.001) (Table 1).
Approximately 10% of the patients with diabetes
suffered from CVA between 2000 and 2009 with men having
slightly predominant rates (Table 2). The prevalence of
stroke showed a steady decrease in both genders in the past
10 years. The prevalence of CVD gradually decreased from
38.14% in 2000 to 33.43% in 2009 (p for trend <0.001), but
was higher in diabetic women (34.7%) than in diabetic men
(32.2%) (Table 3). The prevalence of PVD increased from
1.87% in 2000 to 2.47% in 2009. There was no gender
difference, and PVD was more likely to occur in elderly
patients (Table 4).
For patients with diabetes who are diagnosed with
several microvascular complications, including eye disease,
low vision/blindness, all kinds of nephropathy, chronic
renal failure/transplantation/dialysis, and all kinds of
dialysis, the prevalence of dyslipidemia was relatively
stable during the 2000e2009 study period, except in
patients with eye disease and those in both genders who
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628 L.-N. Tseng et al.underwent dialysis (Table 5). Although the prevalence of
diabetes plus dyslipidemia decreased in patients with CVD,
including those with MI and CVA, it increased in patients
with PVD from 2000 to 2009 (p for all trends <0.001)
(Table 6).
The prevalence of hypertension increased in patients
with microvascular complications, including all kinds of
retinopathy, patients (in both genders) on dialysis, and in
men with nephropathy (Table 7), while it decreased in
patients with macrovascular complications, except those
with PVD in both genders (Table 7). The prevalence of
hypertension plus dyslipidemia increased in patients with
all kinds of retinopathy, patients on dialysis, and in men
with nephropathy. In contrast, the prevalence of hyper-
tension plus dyslipidemia decreased in patients with all
macrovascular complications in both genders except in
those with PVD (Table 7).Discussion
Metabolic syndrome is characterized by obesity, glucose
intolerance, elevated blood pressure (BP), and dyslipide-
mia. Each component of metabolic syndrome predisposes
people to atherosclerosis, and when clustered together,
these components promote atherosclerosis even more
prominently. Dai and colleagues studied 1494 healthy
Taiwanese patients aged >40 years in 1992e1993 at Taipei
City and San-Tze village, and found that the prevalence of
each component of metabolic syndrome was as follows:
obesity, 29.7%; high triglyceride (TG) levels, 21.7%; low
high-density lipoprotein cholesterol (HDL-c) level, 35.9%;
high BP, 56.9%; and impaired fasting glucose, 13.1%.11 Our
present study showed that there was an obvious trend of
increased prevalence of hypertension, dyslipidemia, and
combined hypertension and dyslipidemia in patients with
diabetes from 2000 to 2009. Until 2009, 64.47% of patients
with diabetes had hypertension, 42.22% of patients with
diabetes had dyslipidemia, and 30.09% of them had both
(Table 1). In both genders, the peak age for dyslipidemia
was 40e65 years, while the peak age for hypertension was
>65 years.
Dyslipidemia is a major risk factor for macrovascular
complications in patients with type 2 diabetes.12 Further-
more, type 2 diabetes increases the risk for CVD mortality
independent of low-density lipoprotein cholesterol (LDL-c)
levels, adding to the greater overall cardiovascular risk in
this population.13 The dyslipidemia associated with insulin
resistance is characterized by moderately increased TG
levels carried in very-low-density lipoprotein particles, and
reduced HDL-c carried in small HDL particles.5 In patients
with type 2 diabetes, LDL particles are small and dense,
and carry less cholesterol per particle; therefore, at any
given LDL-c concentration, more LDL particles are present
in an individual with type 2 diabetes compared with those
without the disease.5
Data from the United States National Health and Nutri-
tional Examination Survey (NHANES) 1999e2000 showed
that <50% of adults having diabetes had total cholesterol
(TC) levels <200 mg/dL despite >50% of these patients
receiving medication for dyslipidemia.12 Also, among the
patients with type 2 diabetes receiving treatment for
Table 2 Number of cases and prevalence of stroke in individuals with diabetes by gender and age in Taiwan, 2000e2009.
Year P for trend
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
F Age group <40 Number 168 171 186 273 210 225 237 273 222 255
Prevalence 0.89% 1.12% 1.10% 1.60% 1.14% 1.21% 1.22% 1.33% 1.05% 1.25% 0.439
40e65 Number 11,004 11,160 12,024 13,017 13,191 13,323 13,254 13,935 14,412 14,361
Prevalence 6.15% 5.97% 6.02% 6.19% 5.84% 5.66% 5.39% 5.35% 5.25% 5.25% <0.001
>65 Number 25,965 27,234 30,594 33,513 35,334 37,611 38,739 41,235 43,104 43,560
Prevalence 15.69% 15.25% 15.70% 16.03% 15.52% 15.39% 14.90% 14.78% 14.40% 14.16% 0.002
Total Number 37,137 38,565 42,804 46,803 48,735 51,159 52,230 55,443 57,738 58,176
Prevalence 10.22% 10.12% 10.40% 10.72% 10.32% 10.26% 9.94% 9.90% 9.70% 9.67% 0.02
M Age group <40 Number 309 351 291 456 438 465 402 444 540 483
Prevalence 1.40% 1.64% 1.25% 1.86% 1.63% 1.67% 1.38% 1.45% 1.68% 1.56% 0.712
40e65 Number 12,714 13,398 14,862 16,317 17,466 18,450 19,317 20,577 21,909 22,539
Prevalence 7.11% 6.92% 6.95% 7.04% 6.81% 6.76% 6.67% 6.60% 6.52% 6.57% <0.001
>65 Number 23,883 25,020 28,179 30,861 32,388 34,746 36,222 38,619 41,121 41,715
Prevalence 16.86% 16.58% 17.24% 17.76% 17.22% 17.36% 17.14% 17.09% 17.04% 16.88% 0.883
Total Number 36,906 38,769 43,332 47,634 50,292 53,661 55,941 59,640 63,570 64,737
Prevalence 10.77% 10.60% 10.81% 11.07% 10.67% 10.71% 10.56% 10.50% 10.43% 10.42% 0.030-
All stroke in DM 74,079 77,394 86,193 94,497 99,135 104,820 108,174 115,083 121,308 122,913
% stroke in DM 10.48% 10.35% 10.60% 10.88% 10.49% 10.49% 10.25% 10.20% 10.07% 10.05% 0.025
DMZ diabetes mellitus.
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Table 3 Number of cases and prevalence of cardiovascular disease in individuals with diabetes by gender and age in Taiwan, 2000e2009.
Year P for trend
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
F Age group <40 Number 1,680 1,515 1,521 1,467 1,506 1,509 1,422 1,644 1,539 1,536
Prevalence 8.87% 9.91% 9.00% 8.60% 8.15% 8.11% 7.34% 8.01% 7.25% 7.51% 0.001
40e65 Number 58,212 58,668 60,549 62,709 66,525 67,416 68,535 71,700 73,536 71,922
Prevalence 32.51% 31.36% 30.33% 29.80% 29.44% 28.64% 27.87% 27.55% 26.77% 26.27% <0.001
>65 Number 85,482 90,249 96,987 101,721 110,274 117,081 121,656 127,974 134,256 135,327
Prevalence 51.67% 50.55% 49.76% 48.64% 48.43% 47.90% 46.80% 45.86% 44.86% 44.00% <0.001
Total Number 145,374 150,432 159,057 165,897 178,305 186,006 191,613 201,318 209,331 208,785
Prevalence 40.00% 39.49% 38.66% 38.00% 37.77% 37.32% 36.48% 35.96% 35.17% 34.70% <0.001
M Age group <40 Number 2,292 2,262 2,508 2,571 2,853 3,024 3,087 3,243 3,435 3,441
Prevalence 10.38% 10.60% 10.76% 10.47% 10.64% 10.83% 10.58% 10.63% 10.69% 11.12% 0.045
40e65 Number 50,016 52,644 56,826 60,519 68,148 72,132 76,425 81,486 86,724 89,142
Prevalence 27.97% 27.21% 26.56% 26.10% 26.56% 26.42% 26.41% 26.14% 25.79% 25.99% 0.003
>65 Number 71,694 74,187 79,023 82,440 88,251 93,597 96,765 101,985 106,767 107,397
Prevalence 50.60% 49.17% 48.33% 47.44% 46.93% 46.76% 45.80% 45.13% 44.25% 43.47% <0.001
Total Number 124,002 129,093 138,357 145,530 159,252 168,753 176,277 186,714 196,926 199,980
Prevalence 36.20% 35.30% 34.53% 33.83% 33.78% 33.67% 33.27% 32.86% 32.30% 32.20% <0.001
All CVD in DM 269,613 279,798 297,750 311,805 337,926 354,765 367,890 388,032 406,257 408,765
% CVD in DM 38.14% 37.42% 36.60% 35.90% 35.76% 35.49% 34.87% 34.40% 33.72% 33.43% <0.001
CVDZ cardiovascular disease.
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Table 4 Number of cases and prevalence of peripheral vascular disease in individuals with diabetes stratified by gender nd age in Taiwan, 2000e2009.
Year p for trend
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
F Age group <40 Number 63 99 69 93 120 132 105 126 126 165 d
Prevalence 0.33% 0.65% 0.41% 0.55% 0.65% 0.71% 0.54% 0.61% 0.59% 0.81% 0.042
40e65 Number 2,745 2,763 2,811 3,141 3,987 4,185 4,488 4,731 5,250 5,394 d
Prevalence 1.53% 1.48% 1.41% 1.49% 1.76% 1.78% 1.83% 1.82% 1.91% 1.97% <0.001
>65 Number 4,125 4,323 4,746 5,322 6,657 7,350 8,055 8,598 9,471 9,819 d
Prevalence 2.49% 2.42% 2.43% 2.54% 2.92% 3.01% 3.10% 3.08% 3.16% 3.19% <0.001
Total Number 6,933 7,185 7,626 8,556 10,764 11,667 12,648 13,455 14,847 15,378 d
Prevalence 1.91% 1.89% 1.85% 1.96% 2.28% 2.34% 2.41% 2.40% 2.49% 2.56% <0.001
M Age group <40 Number 96 81 105 108 165 177 240 237 240 225 d
Prevalence 0.43% 0.38% 0.45% 0.44% 0.62% 0.63% 0.82% 0.78% 0.75% 0.73% <0.001
40e65 Number 2,529 2,658 3,138 3,456 4,101 4,674 5,031 5,250 5,853 6,333 d
Prevalence 1.41% 1.37% 1.47% 1.49% 1.60% 1.71% 1.74% 1.68% 1.74% 1.85% <0.001
>65 Number 3,636 3,795 4,155 4,812 5,640 6,387 7,050 7,605 8,253 8,310 d
Prevalence 2.57% 2.52% 2.54% 2.77% 3.00% 3.19% 3.34% 3.37% 3.42% 3.36% <0.001
Total Number 6,261 6,534 7,398 8,376 9,906 11,238 12,321 13,092 14,346 14,868 d
Prevalence 1.83% 1.79% 1.85% 1.95% 2.10% 2.24% 2.33% 2.30% 2.35% 2.39% <0.001
All PVD in DM 13,197 13,719 15,024 16,944 20,685 22,905 24,969 26,547 29,193 30,246 d
% PVD in DM 1.87% 1.83% 1.85% 1.95% 2.19% 2.29% 2.37% 2.35% 2.42% 2.47% <0.001
DM Z diabetes mellitus; PVD Z peripheral vascular disease.
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632 L.-N. Tseng et al.dyslipidemia, control of LDL-c was only achieved in 29.7%.12
Consistent with the data from the NHANES 1999e2000, data
from the United Kingdom Prospective Diabetes Study in
3713 patients newly diagnosed with type 2 diabetes showed
that HDL-c levels were lower (by 9% in men and 23% in
women), while TG levels were 50% higher in patients with
type 2 diabetes than in nondiabetic patients. This kind of
dyslipidemia pattern was more pronounced in females, so it
was suggested to contribute to the greater cardiovascular
risk in females compared with males.3 Lin et al investigated
408 drug-naı¨ve patients with type 2 diabetes in central
Taiwan, and found that among diabetic men, the plasma TG
level was positively correlated with the waist-to-hip ratio
(WHR) and alcohol consumption, whereas HDL-c was
negatively correlated with age and body mass index.14 A
nationwide survey to evaluate the status of diabetes
control in 7542 patients with diabetes in 114 accredited
diabetes health promotion centers in Taiwan revealed that
only 30.9% of patients met the goal of both systolic BP (SBP)
and diastolic BP (DBP) less than 130/80 mmHg, while 35.3%
of patients met the goal of TC less than 160 mg/dL or LDL-c
less than 100 mg/dL.15
In the Western Pacific region, countries with large pop-
ulations (China and Indonesia) and countries with a high
prevalence of diabetes (10% in Malaysia, Hong Kong, and
Singapore) contributed to the growing burden of this
disease,16 but the benefits of lowering lipid levels have not
been systematically demonstrated in the Asian pop-
ulation.17 The Asia Pacific Cohort Studies Collaboration
meta-analysis examined lipid associations with coronary
heart disease (CHD) and CVD death from 17 Asian cohorts
including Taiwan. They found that the associations of TC,
TG, and HDL-c with CVD were similar to those seen with
CHD, but with a lesser magnitude.17 Data from the Joint
Asia Diabetes Evaluation (JADE) program from eight areas in
Asia including Taiwan also showed that dyslipidemia and
hypertension affected 76.8% and 84.6% of the patients,
respectively.18 In a study conducted by Xu et al in Beijing,
China, the prevalence of lipid disorder was as high as 63.8%
in the Chinese population in the Beijing area.19 From our
analysis of nationwide data, the highest prevalence was in
females aged 40e65 years (46.15%), but this prevalence
was lower than that reported in the JADE program or in the
study by Xu and colleagues in China.18,19
In our analysis, the prevalence of dyslipidemia in
patients with microvascular complications remained stable.
In patients with macrovascular complications, including all
CVD and CVA, the prevalence of associated dyslipidemia
decreased in both genders from 2000 to 2009. These results
may be attributable to an improved health-care system and
promotion of health education in Taiwan.20 In support of
our findings, a diabetic study using data from the Taiwan
NHI database showed that the proportion of statin use
among all lipid-lowering drugs increased from 20.8% in 1997
to 69.0% in 2003.21
Hypertension is one of the most important risk factors
for atherosclerosis-related morbidity and mortality. The
prevalence rate of hypertension is also growing worldwide,
and the rampant increase in prevalence is most serious in
Asia.22 It is predicted that there will be a 65.4% increase in
hypertensive men in Asia by 2025 compared with a 54.4%
increase in the rest of the world. It will be even more
Table 6 Prevalence of macrovascular diseases according to dyslipidemia and gender in individuals with diabetes in Taiwan, 2000e2009.
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 P for trend
dyslipidemia dyslipidemia dyslipidemia dyslipidemia dyslipidemia dyslipidemia dyslipidemia dyslipidemia dyslipidemia dyslipidemia
(+) (e) (+) (-) (+) (-) (+) (-) (+) (-) (+) (-) (+) (-) (+) (-) (+) (-) (+) (-) (+) (e)
% % % % % % % % % % % % % % % % % % % %
PVD F 2.05% 1.87% 2.14% 1.82% 2.04% 1.79% 2.07% 1.90% 2.40% 2.21% 2.46% 2.27% 2.59% 2.29% 2.52% 2.31% 2.68% 2.35% 2.71% 2.05% <0.001 0.014
M 1.63% 1.87% 1.94% 1.75% 2.07% 1.78% 2.08% 1.89% 2.21% 2.05% 2.21% 2.26% 2.39% 2.29% 2.27% 2.33% 2.25% 2.42% 2.33% 1.63% 0.02 0.206
Amputation/
bypass
F 0.46% 0.38% 0.39% 0.39% 0.38% 0.38% 0.36% 0.40% 0.37% 0.42% 0.35% 0.41% 0.33% 0.36% 0.33% 0.36% 0.33% 0.35% 0.37% 0.46% 0.13 0.749
M 0.45% 0.61% 0.53% 0.54% 0.52% 0.52% 0.43% 0.51% 0.48% 0.53% 0.44% 0.54% 0.45% 0.48% 0.38% 0.52% 0.46% 0.53% 0.42% 0.45% 0.074 0.024
CVD F 50.08% 37.60% 48.27% 37.26% 46.77% 35.92% 44.38% 34.92% 43.26% 34.51% 42.53% 34.22% 41.53% 33.16% 40.51% 32.61% 39.09% 32.14% 38.04% 50.08% <0.001 0.613
M 45.37% 34.35% 44.28% 33.38% 42.65% 32.27% 40.85% 31.09% 40.16% 30.73% 39.50% 30.83% 38.89% 30.21% 38.28% 29.53% 37.54% 28.89% 36.95% 45.37% <0.001 0.583
MI F 3.16% 1.49% 3.04% 1.37% 2.93% 1.36% 2.70% 1.29% 2.68% 1.25% 2.64% 1.17% 2.39% 1.13% 2.32% 1.14% 2.32% 1.05% 2.37% 3.16% <0.001 0.351
M 5.79% 2.30% 5.83% 2.22% 5.62% 2.00% 4.98% 1.95% 4.90% 1.88% 4.75% 1.88% 4.82% 1.79% 4.65% 1.80% 4.89% 1.73% 4.91% 5.79% 0.004 0.257
CVA F 12.57% 9.66% 12.17% 9.60% 12.36% 9.74% 12.09% 10.06% 11.29% 9.75% 11.06% 9.79% 10.46% 9.60% 10.29% 9.62% 10.11% 9.38% 9.97% 12.57% <0.001 0.116
M 11.96% 10.53% 12.02% 10.30% 12.22% 10.42% 11.99% 10.71% 11.30% 10.37% 10.90% 10.62% 10.89% 10.38% 10.71% 10.37% 10.57% 10.33% 10.58% 11.96% <0.001 0.195
ICH F 3.68% 2.66% 3.39% 2.58% 3.44% 2.49% 2.91% 2.41% 2.83% 2.42% 2.68% 2.38% 2.60% 2.32% 2.32% 2.38% 2.35% 2.15% 2.28% 3.68% <0.001 0.521
M 3.83% 3.09% 3.74% 3.04% 3.51% 3.00% 3.18% 2.93% 3.15% 2.88% 3.01% 2.98% 3.20% 2.83% 2.77% 2.87% 2.94% 2.86% 2.88% 3.83% <0.001 0.425
CVA-ischemia F 8.95% 6.37% 8.62% 6.32% 8.64% 6.25% 8.59% 6.73% 7.68% 6.30% 7.49% 6.37% 7.26% 6.13% 6.98% 6.18% 6.80% 5.99% 6.73% 8.95% <0.001 0.251
M 8.95% 7.28% 8.91% 7.04% 8.88% 7.10% 8.82% 7.35% 8.10% 6.93% 7.78% 7.12% 7.90% 6.98% 7.64% 6.93% 7.61% 6.87% 7.59% 8.95% <0.001 0.257
(+)Zwith dyslipidemia; (e)Zwithout dyslipidemia; CVAZ cerebrovascular accident; CVDZ cardiovascular disease; ICHZ intracerebral hemorrhage (hemorrhagic stroke);
MIZmyocardial infarction; PVDZ peripheral vascular disease.
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Table 7 Prevalence of co-morbidities and complications according to hypertension (T), dyslipidemia (L) and gender in patients with diabetes in Taiwan, 2000e2009.
2000 2004 2008 P for trend 2000 2004 2008 P for trend 2000 2004 2008 P for
trend
T(+) T(-) T(+) T(-) T(+) T(-) T(+) T(-) L(+) L(-) L(+) L(-) L(+) L(-) L(+) L(-) T+L T+L T+L T+L
Retinopathy F 7.44% 5.25% 9.93% 7.54% 9.89% 7.54% 0.002 0.004 8.54% 6.06% 11.56% 7.55% 10.97% 7.66% 0.038 0.005 9.41% 12.32% 11.73% 0.049
M 7.05% 4.38% 8.96% 5.94% 8.58% 5.93% 0.012 0.001 6.38% 5.67% 9.16% 6.88% 8.51% 6.87% 0.016 0.004 7.50% 10.42% 9.40% 0.021
Low vision/
blindness
F 0.49% 0.34% 0.57% 0.32% 0.61% 0.38% 0.033 0.818 0.51% 0.41% 0.63% 0.38% 0.63% 0.46% 0.525 0.592 0.60% 0.73% 0.70% 0.645
M 0.73% 0.39% 0.63% 0.38% 0.73% 0.34% 0.294 0.813 0.58% 0.57% 0.65% 0.45% 0.68% 0.50% 0.029 0.764 0.74% 0.79% 0.84% 0.171
Nephropathy F 16.32% 8.82% 16.67% 9.38% 16.94% 9.44% 0.083 0.513 17.64% 12.18% 17.33% 11.97% 16.99% 12.43% <0.001 0.973 20.32% 19.67% 19.14% <0.001
M 17.65% 8.76% 18.78% 9.59% 19.62% 10.29% <0.001 0.244 16.04% 12.92% 17.67% 13.28% 18.15% 14.43% <0.001 <0.001 19.70% 21.38% 21.40% 0.002
CRF/dialysis/
transplant
F 4.95% 2.55% 5.11% 2.60% 5.70% 2.67% 0.002 0.260 5.47% 3.60% 4.75% 3.83% 5.10% 4.36% 0.427 0.001 6.39% 5.59% 6.01% 0.589
M 5.72% 2.50% 6.23% 2.56% 7.00% 2.82% <0.001 0.029 4.93% 4.04% 4.89% 4.46% 5.36% 5.31% 0.026 <0.001 6.20% 6.38% 6.86% 0.021
Dialysis F 1.81% 0.99% 2.25% 1.36% 2.80% 1.45% <0.001 <0.001 1.93% 1.37% 1.98% 1.88% 2.32% 2.37% <0.001 <0.001 2.19% 2.21% 2.64% 0.001
M 2.05% 0.97% 2.40% 1.12% 3.06% 1.35% <0.001 <0.001 1.68% 1.51% 1.66% 1.91% 2.03% 2.60% 0.001 <0.001 2.05% 2.17% 2.59% <0.001
PVD F 2.20% 1.49% 2.67% 1.63% 2.85% 1.79% <0.001 <0.001 2.05% 1.87% 2.40% 2.21% 2.68% 2.35% <0.001 0.014 2.32% 2.69% 2.90% <0.001
M 2.11% 1.51% 2.57% 1.52% 2.82% 1.66% <0.001 0.088 1.63% 1.87% 2.21% 2.05% 2.25% 2.42% 0.02 0.206 1.84% 2.61% 2.61% 0.018
CVD F 58.48% 13.75% 51.93% 13.80% 46.23% 13.32% <0.001 0.016 50.08% 37.60% 43.26% 34.51% 39.09% 32.14% <0.001 0.613 63.01% 54.54% 48.20% <0.001
M 57.77% 12.20% 50.65% 12.68% 45.10% 13.06% <0.001 0.001 45.37% 34.35% 40.16% 30.73% 37.54% 28.89% <0.001 0.583 61.39% 53.53% 47.99% <0.001
MI F 2.55% 0.76% 2.36% 0.81% 2.03% 0.76% <0.001 0.281 3.16% 1.49% 2.68% 1.25% 2.32% 1.05% <0.001 0.351 3.93% 3.32% 2.79% <0.001
M 4.15% 1.48% 3.95% 1.49% 3.83% 1.69% 0.007 0.002 5.79% 2.30% 4.90% 1.88% 4.89% 1.73% 0.004 0.257 7.02% 6.13% 5.81% <0.001
Stroke F 14.03% 4.80% 13.51% 4.93% 12.04% 5.08% <0.001 0.330 12.57% 9.66% 11.29% 9.75% 10.11% 9.38% <0.001 0.116 15.26% 13.80% 11.95% <0.001
M 16.05% 4.91% 15.20% 5.00% 13.76% 5.42% <0.001 0.154 11.96% 10.53% 11.30% 10.37% 10.57% 10.33% <0.001 0.195 15.83% 14.99% 13.22% <0.001
Foot
infection
F 1.70% 1.12% 1.46% 0.90% 1.07% 0.59% <0.001 <0.001 1.36% 1.48% 1.18% 1.29% 0.78% 1.01% <0.001 0.001 1.57% 1.42% 0.91% <0.001
M 2.04% 1.62% 1.81% 1.33% 1.41% 0.84% <0.001 <0.001 1.31% 1.95% 1.30% 1.74% 0.92% 1.35% 0.001 0.001 1.58% 1.57% 1.15% 0.001
Amputation F 0.42% 0.27% 0.44% 0.23% 0.35% 0.12% 0.021 <0.001 0.34% 0.36% 0.29% 0.41% 0.24% 0.30% 0.001 0.121 0.38% 0.37% 0.29% 0.004
M 0.58% 0.51% 0.60% 0.38% 0.50% 0.26% 0.009 0.002 0.31% 0.59% 0.41% 0.54% 0.28% 0.49% 0.165 0.059 0.35% 0.52% 0.38% 0.263
(+)Zwith dyslipidemia/hypertension; (e)Zwithout dyslipidemia/hypertension; LZ dyslipidemia; TZ hypertension; T þ LZ hypertension + dyslipidemia; CRFZ chronic renal failure;
CVDZ cardiovascular disease; MIZmyocardial infarction; PVDZ peripheral vascular disease.
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Prevalence of hypertension and dyslipidemia in Taiwan diabetic patients 635severe in women, with an 81.6% increase in Asia compared
with a 54.4% increase in the rest of the world.22 In a recent
survey in Taiwan, the nationwide prevalence rates of
hypertension were 25% in men and 18% in women, and the
rate increased to 47% among individuals aged 60 years.23
The community-based data from a 10-year follow-up
cohort in Taiwan showed that the incidence rates have
increased among individuals with prehypertension, obesity,
and metabolic syndrome.24 In our study, we found that for
patients >65 years of age with diabetes, the prevalence of
hypertension even reached 76.9% in women, and 72.03% in
men. These prevalence rates were similar to those reported
by Long and Dagogo-Jack in the United States.7 According
to a nationwide survey conducted by Yu and colleagues
(2006) in 7541 patients with diabetes in Taiwan, only 30.9%
of patients met the American Diabetes Association goal of
BP maintenance (SBP and DBP less than 130/80 mmHg), but
the percentage of patients with diabetes who fulfilled the
ABC goals was only 4.1%.15 These data reflect the chal-
lenges of treating diabetic patients with hypertension and
dyslipidemia.
Our findings showed that prevalence of CVD was more
markedly increased in women who are aged 40e65 and
>65 years than in men in the same age group. Data from the
Strong Heart Study indicated that diabetic women had
a higher prevalence of MI and CHD than did diabetic men.
The prevalence ratios of MI were 3.8 (1.4e10.1) for diabetic
women and 1.9 (1.2e2.9) for diabetic men.25 The authors
of the study further demonstrated that diabetic women
have increased WHR and have more adverse lipoprotein
change, including greater decreases in HDL-c, apoA1, and
LDL-c size, than do diabetic men.26 Thiazolidinediones,
which are agonists of peroxisomal proliferator-activated
receptor-g, were shown to have cardioprotective effects
and can modify lipid profile. They were introduced in
Taiwan since the early 2000s. Chen and colleagues found
that rosiglitazone significantly reduces plasma levels of
inflammatory biomarkers and restores global endothelial
dysfunction, independently from insulin sensitization in
healthy smokers.27 However, whether the use of glitazones
has some contribution to the overall decreased prevalence
of CHD in patients with diabetes in the past 10 years needs
further large-scale studies.
Mortality from CVA was approximately 2.8-folds higher in
men with diabetes compared with men without diabetes.13
Approximately 80% of strokes result from ischemic cerebral
infarction in the nondiabetic population and cerebral
hemorrhage occurs in the remaining 20% of cases.28 Studies
in diabetic patients have shown a decreased prevalence of
hemorrhagic stroke when compared with nondiabetic
patients.29,30 Our study showed that around 70% of stroke
cases were of the ischemic type. In the Framingham study,
there was a fourfold to fivefold excess risk of hemorrhagic
stroke in patients with diabetes compared with those
without diabetes.31 However, diabetes did not seem to
have any effect on hemorrhagic stroke in a cohort of the
Honolulu Heart Program.32 The younger population had
different risk factors and etiologies of stroke than the older
population. Traditional cardiovascular risk factors, such as
dyslipidemia and hypertension, were common in older
patients, while the major risk factors in younger patients
were congenital or acquired heart disease, or cervicalartery dissection.33 The difference in gender proportion
was larger in the young stroke population, predominantly
with men, than in the older stroke population.34 A similar
effect was found in our study.
In our study, prevalence of PVD in diabetes increased
from 1.87% in 2000 to 2.47% in 2009 with female predomi-
nance and a rapid increase with age. The prevalence of PVD
was approximately two times as high for patients with
diabetes, among whom 10% had lower extremities PVD,
compared with nondiabetic patients.35 The prevalence of
PVD in diabetes might be underestimated because many
people are asymptomatic.35 The causes of increased PVD in
diabetes might be attributable to aging, increased duration
of diabetes, and associated risk factors.36
In conclusion, we observed a progressively increasing
rate of dyslipidemia, hypertension, and dyslipidemia plus
hypertension in patients with diabetes from 2000 to 2009
in Taiwan. However, prevalence of stroke and CVD
decreased from 2000 to 2009. Prevalence of diabetic
dyslipidemia remained stable in those with microvascular
complications and, indeed, it decreased gradually in
patients with macrovascular complications except those
with PVD. In diabetic patients with various macrovascular
complications, the prevalence of hypertension decreased
in the 10-year interval except in those with PVD. As
a result, prevalence of hypertension plus dyslipidemia
slightly decreased in diabetic patients with macrovascular
complications except those with PVD. Although these
trends may be attributable to Taiwan’s recent efforts in
advocating practice guidelines for diabetic care, estab-
lishing diabetes mellitus care institutions and fostering
shared care networks, a certain percentage of patients
remain at the suboptimal control. More aggressive
management of the comorbidities in patients with dia-
betes is clearly warranted.
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